DOI:
10.1055/s-00000030
Der Klinikarzt
LinksClose Window
References
Richardson PG, Jagannath S, Moreau P et al.
A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results.
ASH Annual Meeting Abstracts 2012;
120: 202-202
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.